Shenyang Xingqi PharmaceuticalLtd Management
Management criteria checks 2/4
Shenyang Xingqi PharmaceuticalLtd's CEO is E. Gao, appointed in Jul 2022, has a tenure of 2.5 years. directly owns 1.19% of the company’s shares, worth CN¥145.43M. The average tenure of the management team and the board of directors is 13.2 years and 4 years respectively.
Key information
E. Gao
Chief executive officer
CN¥2.1m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 2.5yrs |
| CEO ownership | 1.2% |
| Management average tenure | 13.2yrs |
| Board average tenure | 4yrs |
Recent management updates
Recent updates
These 4 Measures Indicate That Shenyang Xingqi PharmaceuticalLtd (SZSE:300573) Is Using Debt Safely
Jan 05
Shenyang Xingqi Pharmaceutical Co.,Ltd.'s (SZSE:300573) P/E Is Still On The Mark Following 49% Share Price Bounce
Oct 23Shenyang Xingqi Pharmaceutical Co.,Ltd. (SZSE:300573) Stocks Pounded By 30% But Not Lagging Market On Growth Or Pricing
Sep 08With EPS Growth And More, Shenyang Xingqi PharmaceuticalLtd (SZSE:300573) Makes An Interesting Case
Aug 19What You Can Learn From Shenyang Xingqi Pharmaceutical Co.,Ltd.'s (SZSE:300573) P/S After Its 27% Share Price Crash
Jul 24Does Shenyang Xingqi PharmaceuticalLtd (SZSE:300573) Have A Healthy Balance Sheet?
Jun 28Shenyang Xingqi PharmaceuticalLtd (SZSE:300573) Is Increasing Its Dividend To CN¥3.00
May 21After Leaping 31% Shenyang Xingqi Pharmaceutical Co.,Ltd. (SZSE:300573) Shares Are Not Flying Under The Radar
May 10We Ran A Stock Scan For Earnings Growth And Shenyang Xingqi PharmaceuticalLtd (SZSE:300573) Passed With Ease
May 07Shenyang Xingqi Pharmaceutical Co.,Ltd. (SZSE:300573) Looks Just Right With A 26% Price Jump
Mar 15CEO
E. Gao (50 yo)
2.5yrs
Tenure
CN¥2,079,000
Compensation
Ms. E. Gao serves as General Manager and MD at Shenyang Xingqi Pharmaceutical Co., Ltd. since July 18, 2022 and served as its Deputy General Manager until July 18, 2022. Ms. Gao serves as Director of Liaon...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD, GM & Non-Independent Director | 2.5yrs | CN¥2.08m | 1.19% CN¥ 145.4m | |
| Deputy Chairman | 10yrs | CN¥2.08m | 0.73% CN¥ 88.9m | |
| Deputy GM | 13.2yrs | CN¥1.70m | 0.21% CN¥ 26.0m | |
| Director of the Administrative Management Department & Director | no data | CN¥1.43m | 0.041% CN¥ 5.0m | |
| Head of R&D Center | no data | CN¥1.32m | 0.13% CN¥ 15.4m | |
| Head of the Accounting Department & Accounting Supervisor | no data | no data | no data | |
| Human Resources Specialist & Employee Representative Supervisor | no data | no data | no data |
13.2yrs
Average Tenure
48.5yo
Average Age
Experienced Management: 300573's management team is seasoned and experienced (13.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD, GM & Non-Independent Director | 13.2yrs | CN¥2.08m | 1.19% CN¥ 145.4m | |
| Deputy Chairman | 10yrs | CN¥2.08m | 0.73% CN¥ 88.9m | |
| Deputy GM | 7yrs | CN¥1.70m | 0.21% CN¥ 26.0m | |
| Director of the Administrative Management Department & Director | 2.9yrs | CN¥1.43m | 0.041% CN¥ 5.0m | |
| Head of R&D Center | 7.7yrs | CN¥1.32m | 0.13% CN¥ 15.4m | |
| Human Resources Specialist & Employee Representative Supervisor | 1yr | no data | no data | |
| Chairman of the Board | 13.2yrs | CN¥6.00m | 28.47% CN¥ 3.5b | |
| Independent Director | 4yrs | CN¥106.80k | no data | |
| Chairman of the Supervisory Board | 4yrs | no data | no data | |
| Independent Director | 1yr | no data | no data | |
| Independent Director | 1yr | no data | no data | |
| Supervisor | 1yr | no data | no data |
4.0yrs
Average Tenure
48.5yo
Average Age
Experienced Board: 300573's board of directors are considered experienced (4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/31 01:50 |
| End of Day Share Price | 2025/01/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Shenyang Xingqi Pharmaceutical Co.,Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tielin Chen | Topsperity Securities |
| Jing Chen | Topsperity Securities |